Pharmaceutical supply-chain team reviewing manufacturing documentation

Multi-product portfolio · U.S. market

Asia to United States

Capacity and single-source risk governance

A representative mandate connecting demand, line-slot allocation, material coverage, and qualified secondary pathways.

Representative scenario. Outcomes and targets are illustrative and require calibration to the company’s verified baseline.

Executive context

The mandate behind the operating problem

A multi-product portfolio depended on constrained Asian manufacturing assets and several single-source API and KSM pathways, while demand and campaign plans were managed in separate planning views.

The company needed a forward-looking governance model that converted demand uncertainty into capacity, material, qualification, and commercial decisions.

Intervention design

One governed path, not parallel status reports

01

Rolling capacity model by SKU, campaign, and constrained asset

02

API/KSM dependency map with inventory and qualification status

03

Commercial governance for yield loss, surcharges, and allocation terms

04

Decision gates for secondary-source and alternate-site activation

Monthly

Demand, capacity, campaign, and material reconciliation by priority SKU.

Quarterly

Commercial and continuity steering against evolving constraints.

Trigger-based

Secondary-path activation when inventory, lead-time, or allocation thresholds move.

Illustrative operating outcomes

Measured against a documented baseline

Targets are established after diagnostic baselining and verified through the evidence protocol below. They are not performance guarantees.

12–18 mo

Illustrative forward-capacity planning target

2-path

Critical supply-continuity target

100%

Priority SKUs mapped to constrained assets

Operating outcome

  • Longer forward capacity visibility
  • Prioritized dual-path qualification decisions
  • More disciplined landed-COGS and continuity trade-offs
  • Clear executive choices before constraints became supply events

Evidence set

  • SKU-to-asset capacity model
  • API/KSM dependency register
  • Inventory and qualification status
  • Commercial term and landed-COGS baseline
Pharmaceutical raw-material inventory under warehouse control

Confidential project review

Apply this governance model to your manufacturing gap

Share the product stage, market, and CMO/CDMO constraint. Elyzora will frame the critical path, evidence requirements, and intervention scope for qualification.

sales.elyzora@gmail.com